Login to Your Account

Galaxy Hooks Roche for Preclinical Oncology Program

By Marie Powers
Staff Writer

Tuesday, September 25, 2012
Galaxy Biotech LLC jumped back into the big fish pond, inking exclusive worldwide development and commercialization rights to a humanized monoclonal antibody (mAb) targeting fibroblast growth factor 2 (FGF2) in cancer to Roche AG.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription